Lee, Hyemin http://orcid.org/0000-0002-7387-5452
Horbath, Amber http://orcid.org/0000-0003-1482-8637
Kondiparthi, Lavanya
Meena, Jitendra Kumar http://orcid.org/0000-0003-0199-9357
Lei, Guang http://orcid.org/0000-0002-3282-0666
Dasgupta, Shayani
Liu, Xiaoguang http://orcid.org/0000-0001-6977-5128
Zhuang, Li
Koppula, Pranavi http://orcid.org/0000-0002-7567-1891
Li, Mi http://orcid.org/0000-0002-6038-4144
Mahmud, Iqbal http://orcid.org/0000-0001-7729-8122
Wei, Bo
Lorenzi, Philip L. http://orcid.org/0000-0003-0385-7774
Keyomarsi, Khandan http://orcid.org/0000-0002-5440-0849
Poyurovsky, Masha V.
Olszewski, Kellen
Gan, Boyi http://orcid.org/0000-0001-8884-6040
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP230072)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA181196, R01CA244144, R01CA247992, R01CA269646, U54 CA274220)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 15 March 2023
Accepted: 12 December 2023
First Online: 2 January 2024
Competing interests
: B.G. reports receiving consultation fees from Guidepoint Global, Cambridge Solutions, and NGM Bio, and is an inventor with patent applications involving targeting ferroptosis in cancer therapy. K.O. and L.K. are former full-time employees of Kadmon Corporation and are now full-time employees of the Carl Icahn Labs and Sanofi, US, respectively. M.V.P. is a former full-time employee of Kadmon Corporation and is now a full-time employee at PMV Pharmaceutics. The other authors declare no competing interests.